YSB (09885) repurchased 100,000 shares on October 20th.
Pharmacist Association (09885) issued an announcement on October 20, 2025. The company will conduct a share buyback in 2025...
YSB (09885) has announced that on October 20, 2025, the company has repurchased shares based on the share buyback authorization for 2025. A total of 100,000 shares have been repurchased in the market, with a total repurchase amount of approximately HK$1.0791 million (excluding commissions and other expenses), at an average repurchase price of HK$10.7907 per share. The repurchased shares will be cancelled in due course.
The Board of Directors believes that the current stock price of the company is lower than its true value and does not fully reflect its business prospects. The Board of Directors believes that the share buyback plan demonstrates the confidence of the directors and senior management of the company in the long-term growth and market performance of the company. The Board of Directors also believes that the share buyback plan is in the overall best interests of the company and its shareholders.
Related Articles

JACOBIO-B(01167) spent 990,000 Hong Kong dollars to repurchase 12,690 shares on October 20th.

Guiyang Xintian Pharmaceutical (002873.SZ) controlling shareholder New Sky Intelligent Medicine plans to reduce holdings by no more than 7.05 million shares.

The actual controller of Shenzhen Etmade Automatic Equipment (300812.SZ) intends to transfer 5% of the shares to Qianji Investment Agreement.
JACOBIO-B(01167) spent 990,000 Hong Kong dollars to repurchase 12,690 shares on October 20th.

Guiyang Xintian Pharmaceutical (002873.SZ) controlling shareholder New Sky Intelligent Medicine plans to reduce holdings by no more than 7.05 million shares.

The actual controller of Shenzhen Etmade Automatic Equipment (300812.SZ) intends to transfer 5% of the shares to Qianji Investment Agreement.

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025